During the past decade, Regional Gastroenterology Associates of Lancaster, Ltd. conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 7 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Regional Gastroenterology Associates of Lancaster, Ltd." #1 sponsor was "Gilead Sciences" with 3 trials, followed by "Pfizer" with 3 trials sponsored, "Braintree Laboratories" with 1 trials sponsored, "Chugai Pharma USA" with 1 trials sponsored and "Colotech A/S" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Regional Gastroenterology Associates of Lancaster, Ltd." #1 collaborator was "Novartis" with 1 trials as a collaborator and "Sucampo Pharmaceuticals, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Regional Gastroenterology Associates of Lancaster, Ltd." are "Ulcerative Colitis" (3 trials), "Colorectal Cancer" (2 trials), "Gastroparesis" (2 trials), "Hepatitis C, Chronic" (2 trials) and "Adenomatous Polyps" (1 trials). Many other conditions were trialed in "Regional Gastroenterology Associates of Lancaster, Ltd." in a lesser frequency.

Most popular intervention types in "Regional Gastroenterology Associates of Lancaster, Ltd." are "Drug" (12 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "CP-690,550" (2 trials), "0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)" (1 trials), "75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)" (1 trials) and "All eligible subjects will provide blood for SEPT9 biomarker testing" (1 trials). Other intervention names were less common.

The vast majority of trials in "Regional Gastroenterology Associates of Lancaster, Ltd." are 16 trials for "All" genders.

Currently, there are NaN active trials in "Regional Gastroenterology Associates of Lancaster, Ltd.". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Regional Gastroenterology Associates of Lancaster, Ltd., undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Regional Gastroenterology Associates of Lancaster, Ltd., 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".